Saudi Chemical subsidiary inks pact to secure exclusive licensing rights for cancer drug

Logo of AJA Pharmaceutical Industries Ltd. (AJA Pharma)

Saudi Chemical Co. Holding (SCCH) signed today, Jan. 31, an exclusive agreement, through its pharmaceutical subsidiary AJA Pharmaceutical Industries Ltd. (AJA Pharma), with Bioventure FZ-LLC, a subsidiary of GlobalOne Healthcare Holding.

The deal was signed in the Saudi Export stand during Arab Health Exhibition 2023.

Under the agreement, AJA Pharma will get exclusive licensing rights for the drug “Ruxolitinib”, a type of cancer drug used to treat some types of neoplasms, the firm said in a statement on Tadawul.

Accordingly, AJA Pharma will have exclusive commercialization rights of Ruxolitinib in the Kingdom, the rest of the GCC, and Arab Levant countries. The subsidiary will have rights to the future transfer of the technology for manufacturing the drug in Saudi Arabia.

AJA Pharma aims to strengthen its position in Saudi and global markets in the field of oncology, diabetes and specialty products, to serve and meet community needs in line with Saudi Vision 2030 objectives to localize value-added specialty drugs.